{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Development of acute graft-vs-host-disease (aGvHD) within 6 months, for participants receiving Allo-HCT.","groups":[{"description":"Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue \\[ie, autologous hematopoietic cells transplant (Auto-HCT)\\]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 \\& Day 0, to a target of \\> 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV \\& diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.","id":"OG000","title":"Auto- Then Allo-HCT"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Graft versus host disease (aGvHD) only occurs in participants receiving Allo-HCT, as determined by investigator judgement (no protocol-specified criteria).","reportingStatus":"POSTED","timeFrame":"6 months","title":"Acute Graft-vs-Host-Disease (aGvHD)","type":"SECONDARY","unitOfMeasure":"Participants"}